Review
First-line therapeutic strategies in metastatic colorectal cancer
Affiliations
- PMID: 19133603
Item in Clipboard
Review
First-line therapeutic strategies in metastatic colorectal cancer
Oncology (Williston Park).
.
Free article
Abstract
The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years. This review traces the evolution of treatment in this setting, including studies of single-agent vs combination treatment with 5-FU/leucovorin, irinotecan, oxaliplatin, and capecitabine, comparisons of simultaneous and sequential regimens, and the role of targeted agents such as bevacizumab, cetuximab, and panitumumab.
Comment on
-
Individualizing therapy for metastatic colorectal cancer.Oncology (Williston Park). 2008 Nov 30;22(13):1479-81. Oncology (Williston Park). 2008. PMID: 19227569 No abstract available.
-
Picking the right road for metastatic colorectal cancer patients.Oncology (Williston Park). 2008 Nov 30;22(13):1482-3. Oncology (Williston Park). 2008. PMID: 19227576 No abstract available.
Similar articles
-
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1. Magy Onkol. 2009. PMID: 19793687 Review. Hungarian.
-
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.Clin Colorectal Cancer. 2008 Mar;7(2):110-7. doi: 10.3816/CCC.2008.n.015. Clin Colorectal Cancer. 2008. PMID: 18501070 Review.
-
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.Clin Colorectal Cancer. 2008 Jul;7(4):226. doi: 10.3816/CCC.2008.n.030. Clin Colorectal Cancer. 2008. PMID: 18650190 No abstract available.
-
[Recent results of irinotecan therapy in colorectal cancer].Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17. Magy Onkol. 2004. PMID: 15655572 Review. Hungarian.
-
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S16-20. doi: 10.3816/ccc.2008.s.003. Clin Colorectal Cancer. 2007. PMID: 18361802 Review.
Cited by
-
Novel strategies for treating relapsed/refractory urothelial carcinoma.Expert Rev Anticancer Ther. 2010 Dec;10(12):1917-32. doi: 10.1586/era.10.182. Expert Rev Anticancer Ther. 2010. PMID: 21110758 Free PMC article. Review.
-
ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.Mol Cancer Ther. 2013 Dec;12(12):2782-91. doi: 10.1158/1535-7163.MCT-13-0098. Epub 2013 Oct 16. Mol Cancer Ther. 2013. PMID: 24132143 Free PMC article.
-
miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.Mol Oncol. 2014 Feb;8(1):83-92. doi: 10.1016/j.molonc.2013.09.004. Epub 2013 Oct 8. Mol Oncol. 2014. PMID: 24145123 Free PMC article.
-
Endothelial cells in colorectal cancer.World J Gastrointest Oncol. 2019 Nov 15;11(11):946-956. doi: 10.4251/wjgo.v11.i11.946. World J Gastrointest Oncol. 2019. PMID: 31798776 Free PMC article. Review.
-
Assessment of neuropathic pain in cancer patients.Curr Pain Headache Rep. 2009 Aug;13(4):282-7. doi: 10.1007/s11916-009-0045-6. Curr Pain Headache Rep. 2009. PMID: 19586591 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
